Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs

Dalbavancin is a novel, long-acting lipoglycopeptide characterized by a long elimination half-life coupled with excellent in vitro activity against multidrug-resistant Gram-positives. Although it is currently approved only for the treatment of acute bacterial skin and skin structure infections, an e...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatti, Milo, Andreoni, Massimo, Pea, Federico, Viale, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349200/
https://www.ncbi.nlm.nih.gov/pubmed/34376971
http://dx.doi.org/10.2147/DDDT.S313756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349200/
https://www.ncbi.nlm.nih.gov/pubmed/34376971
http://dx.doi.org/10.2147/DDDT.S313756

Ejemplares similares